Trial Profile
A randomized, open-label study of the effect of PEGASYS [peginterferon alfa-2a] versus Roferon-A (Interferon alfa-2a, Recombinant) on cytogenetic response in patients with chronic myelogenous leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2010
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 24 Jan 2008 New trial record.